Get the Stockscreener App
1.51
1.63%
-0.025
After Hours:
1.52
0.01
+0.66%
Tenax Therapeutics Inc stock is traded at $1.51, with a volume of 1.85M.
It is down -1.63% in the last 24 hours and down -17.49% over the past month.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
See More
Previous Close:
$1.535
Open:
$1.55
24h Volume:
1.85M
Relative Volume:
0.81
Market Cap:
$56.51M
Revenue:
Net Income/Loss:
$-57.91M
P/E Ratio:
-1.0793
EPS:
-1.3991
Net Cash Flow:
$-38.14M
1W Performance:
-18.82%
1M Performance:
-17.49%
6M Performance:
-89.22%
1Y Performance:
-78.37%
1-Day Range:
$1.51
$1.56
1-Week Range:
$1.51
$1.91
52-Week Range:
$1.31
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
1.51 | 56.51M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-26 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-11-26 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-11-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-28-26 | Initiated | Canaccord Genuity | Buy |
| Jul-22-26 | Initiated | Evercore ISI | Outperform |
| Jun-22-26 | Initiated | Chardan Capital Markets | Buy |
| Mar-17-26 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
TENX Stock Drifts Lower As Traders Eye Cash Runway - StocksToTrade
TENX Stock Drifts Lower As Traders Watch Tight Range - Timothy Sykes
Sphera Funds Management Discloses 7.09% Stake in Tenax Therapeutics as of September 2026 - Kalkine Media
Call option shares count toward Sphera’s amended stake disclosure in Tenax Therapeutics (TENX). - Stock Titan
EBIT per share of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
A 2.4M-share position in Tenax Therapeutics (TENX) is reported with no sole voting power. - Stock Titan
Tenax Therapeutics To Amend Level-2 Enrollment Criteria - TradingView
Tenax Therapeutics pauses LEVEL-2 enrollment to implement enrichment after Phase 3 LEVEL learnings - TradingView
Tenax Therapeutics, Inc. Provides Update on Tnx-103 Level and Level-2 Clinical Trials - www.marketscreener.com
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know - Eastern Progress
Independent Director of Tenax Therapeutics Declan Doogan Buys 2,331% More Shares - webull.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to S&P Global BMI Index - marketscreener.com
Director Declan Doogan Buys 53,000 Shares of Tenax Therapeutics Inc (TENX) - GuruFocus
ING Groep NV Exits Tenax Therapeutics Inc (TENX) Position in Ful - GuruFocus
Tenax Therapeutics CFO buys $10,981 in common stock - Investing.com
ING Groep reports zero stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Stock Short Interest Rises to 35.39% - Quiver Quantitative
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com Canada
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com India
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com UK
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy - tipranks.com
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Australia
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Nigeria
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Canada
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com
ADAR1 Capital Management, LLC Expands Tenax Therapeutics Inc (TE - GuruFocus
One manager just reported a 14% holding in Tenax Therapeutics (TENX) - Stock Titan
FMR LLC reports 514,925-share stake in Tenax (NASDAQ: TENX) - Stock Titan
TENX Jumps As Tenax Therapeutics Pivots Phase 3 Strategy - timothysykes.com
Tenax Therapeutics Stock Wobbles After Mixed Phase 3 Data - timothysykes.com
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable? - Yahoo Finance
Sphera Funds Management Boosts Tenax Therapeutics Stake in High-Risk Biotech Bet - GuruFocus
Investment funds tied to Tenax (TENX) 10% owner just bought more stock - Stock Titan
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Stock Titan
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - finance.yahoo.com
TENX Downgraded by Guggenheim -- Rating Updated to Neutral - GuruFocus
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Guggenheim Downgrades TENX to Neutral Amid Uncertain Clinical Ou - GuruFocus
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com Canada
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com UK
Tenax Therapeutics (TENX) Phase 3 Data Spurs Focus on Subgroup B - GuruFocus
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss (TENX:NASDAQ) - Seeking Alpha
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com Nigeria
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com India
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 - Investing News Network
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenax Therapeutics Inc Stock (TENX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Giordano Christopher Thomas | CEO |
Sep 15 '26 |
Buy |
1.82 |
4,850 |
8,837 |
22,174 |
| Giordano Christopher Thomas | CEO |
Sep 11 '26 |
Buy |
1.88 |
6,000 |
11,250 |
17,324 |
| STAAB THOMAS R II | Chief Financial Officer |
Sep 11 '26 |
Buy |
1.94 |
5,675 |
10,981 |
15,675 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 03 '26 |
Buy |
1.78 |
900,000 |
1,604,160 |
6,524,151 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 02 '26 |
Buy |
1.80 |
187,704 |
337,586 |
5,624,151 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 01 '26 |
Buy |
1.80 |
179,058 |
321,570 |
5,436,447 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 31 '26 |
Buy |
1.79 |
403,571 |
722,594 |
5,257,389 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 24 '26 |
Buy |
1.75 |
107,374 |
188,355 |
4,853,818 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 21 '26 |
Buy |
1.77 |
716,369 |
1,266,254 |
4,746,444 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 20 '26 |
Buy |
1.78 |
202,124 |
359,538 |
4,030,075 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):